It was the FSGS Phase 2a result that shot the share price from 38c to a high of 77c which was then torn down by the DKD Phase 2 results.
On-going understanding of the positive FSGS Phase 2a was then lost in the 'noise' of the reaction to the DKD results just 6 weeks later. Illogically, the FSGS trial got tarnished with the same brush.
The March interim reading is ONLY to do with the so-far positive FSGS trial - not the so-far neutral DKD trial.
This confusion over the trials is why DXB has been such a great opportunity.
I expect an even bigger response with a positive outcome for Phase 3 than was experienced with the Phase 2a - partly because it is from a much lower base (than the 38c immediately prior to the Phase 2a results announcement).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)